Adjuvants
US11406704B2 · kind B2 · utility
0Cited by
1References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 20, 2017 |
| Grant date | Aug 9, 2022 |
| Priority date | — |
| Expiry date | Dec 18, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/735
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides novel adjuvants which may be used in combination with one or more antigens to augment, modulate or enhance a host immune response to the one or more antigens. The adjuvants are based on sialic acid binding molecules and may be combined with any type of antigen. The adjuvants may be formulated for mucosal and/or intranasal administration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.